// App-Quantinova.ai

S4085 2016 AHA : Efficacy and Safety of Sacubitril/Valsartan in Patients in NYHA Functional Class IV. An Analysis Of PARADIGM-HF

Researchers

Presenter

  • Jianjian Gong

Principal Investigators

  • Jean Rouleau

  • Scott Solomon

  • Karl Swedberg

  • Michael Zile

  • Martin Lefkowitz

  • Victor Shi

  • Milton Packer

Medical Centers

  • Brigham & Women's Hospital, Boston, MA

  • Baylor Heart and Vascular Hospital, Dallas, TX

  • University of Glasgow, Glasgow, United Kingdom

  • Univeristy of Gothenburg, Gothenburg, Sweden.

  • Ralph H. Johnston Veterans Admin Medical Ctr, Charleston, SC

Locations

  • United States

  • Canada

  • United Kingdom

  • Sweden

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Congestive heart failure

Biomarkers

  • N/A

Drug/Treatment

  • Sacubitril/valsartan

  • Enalapril maleate

  • Valsartan

  • Roxithromycin

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved